PillRx only · Aerosol, Metered · Respiratory (Inhalation)
Glycopyrrolate And Formoterol Fumarate
Brands: Bevespi Aerosphere · Formoterol Fumarate + Glycopyrrolate
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
ATC—
RxCUI (US)—
US makers1 labelers
Packages1
DEA / ScheduleNone
US acquisition costNADAC · per unit
Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$40.872
Latest avg · Jul 22, 2026
+3%
Since Dec 17, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
5.7K
Rx · 2026 Q1
64K
Units dispensed
-24%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Mar 15, 2021RECALLRecall (Class II): Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) Inhalation Aerosol 9 mcg/4.8 mcg per inhalation For Oral In…
CGMP Deviations: Intermittent exposure to temperature excursion during storage. — Recalling firm: Cardinal Health Inc. — FL, GA, SC